Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProPrems
- Development stage
- Unknown
- Lead developer
- Neobiomics
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
ProPrems is a specific multi-strain probiotic formulation consisting of *Bifidobacterium infantis* (strain Bb-02), *Bifidobacterium lactis* (strain Bb-12), and *Streptococcus thermophilus* (strain TH-4). It was developed primarily for use in the ProPrems trial, a large-scale multicenter randomized controlled trial conducted in Australia and New Zealand to evaluate the efficacy of probiotics in preventing necrotizing enterocolitis (NEC) in very preterm infants (born at less than 32 weeks' gestation and weighing less than 1500g). The mechanism of action involves the competitive exclusion of pathogenic bacteria, enhancement of the intestinal epithelial barrier function, and modulation of the immature mucosal immune system. By establishing a healthy commensal microbiota, ProPrems aims to reduce the incidence of NEC and late-onset sepsis, which are significant causes of morbidity and mortality in the neonatal intensive care unit.
- Brand names
- ProPrems
- Other names
- Bb-02 + Bb-12 + TH-4
Beyond the preview
Go deeper on ProPrems.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProPrems.